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Abstract
OBJECTIVE—T-cell activation independently predicts mortality, poor immune recovery and 
non-AIDS illnesses during combination antiretroviral therapy (cART). Atorvastatin showed anti-
immune activation effects among HIV-infected cART-naïve individuals. We investigated whether 
adjunct atorvastatin therapy reduces T-cell activation among cART-treated adults with suboptimal 
immune recovery.
METHODS—A randomised double-blind placebo-controlled crossover trial, of atorvastatin 80 
mg daily vs. placebo for 12 weeks, was conducted among individuals with CD4 increase <295 
cells/μl after seven years of suppressive cART. Change in T-cell activation (CD3 + CD4 + /CD8 + 
CD38 + HLADR+) and in T-cell exhaustion (CD3 + CD4 + /CD8 + PD1 + ) was measured using 
flow cytometry.
RESULTS—Thirty patients were randomised, 15 to each arm. Atorvastatin resulted in a 28% 
greater reduction in CD4 T-cell activation (60% reduction) than placebo (32% reduction); P = 
0.001. Atorvastatin also resulted in a 35% greater reduction in CD8-T-cell activation than placebo 
(49% vs. 14%, P = 0.0009), CD4 T-cell exhaustion (27% vs. 17% in placebo), P = 0.001 and CD8 
T-cell exhaustion (27% vs. 16%), P = 0.004. There was no carry-over/period effect. Expected 
adverse events were comparable in both groups, and no serious adverse events were reported.
CONCLUSION—Atorvastatin reduced T-cell immune activation and exhaustion among cART-
treated adults in a Ugandan cohort. Atorvastatin adjunct therapy should be explored as a strategy 
to improve HIV treatment outcomes among people living with HIV in sub-Saharan Africa.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and 
reproduction in any medium, provided the original work is properly cited.
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Introduction
The HIV/AIDS pandemic remains a major challenge to global health with 34 million people 
living with HIV (PLHIV) worldwide. The sub-Saharan Africa (SSA) region accounts for 
69% of all PLHIV, 68% of new HIV infections among adults and 72% of the world’s AIDS-
related deaths (UNAIDS 2012). Access to life-saving combination antiretroviral therapy 
(cART) has increased exponentially in the last 5 years, and up to 6 million people are 
receiving cART (WHO/UNAIDS/UNICEF 2011; UNAIDS 2012). With increasing numbers 
of PLHIV receiving cART for long periods, there is a need to optimise effectiveness of 
cART.
Evidence suggests that up to 40% of individuals exhibit suboptimal immune recovery during 
cART despite sustained viral suppression (Nakanjako et al. 2008). Among other factors, the 
immune activation associated with chronic HIV infection interferes with immunological 
recovery during suppressive cART (Hunt et al. 2011; Nakanjako et al. 2011). Our team 
previously reported persistent T-cell activation and exhaustion associated with suboptimal 
immune recovery after 4 years of suppressive cART (Nakanjako et al. 2011). Among 
Ugandan HIV-infected adults starting cART at CD4 < 200 cells/μl and achieving a plasma 
HIV RNA load <400 copies/ml, pre-cART immune activation independently predicted 
increased mortality (Hunt et al. 2011). Chronic persistent immune activation contributes to 
CD4 depletion in both untreated and successfully treated patients and increases the risk of 
non-AIDS-defining illnesses (NADIS), such as chronic kidney and coronary artery disease 
among PLHIV (Hunt et al. 2003, 2008; Gupta et al. 2009; Crowe et al. 2010). Therefore, 
novel therapeutic strategies aimed at preventing or reversing immune activation during 
cART are needed to maximise immune recovery and reduce HIV-associated morbidity and 
mortality among PLHIV in Africa.
Atorvastatin is a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, licensed and 
widely marketed for treatment of dyslipidaemia. However, a recent trial in the USA showed 
that short-term daily use of high-dose atorvastatin caused significant reductions in T-cell 
activation among HAART-naive, viremic, HIV-infected individuals (Ganesan et al. 2011). 
We therefore hypothesised that atorvastatin (80 mg daily for 12 weeks) could reduce 
immune activation levels among cART-treated suboptimal immune responders (SO-IR). In a 
randomised crossover placebo-controlled trial, we determined the anti-immune activation 
effects of 12 weeks of atorvastatin 80 mg daily vs. placebo, among SO-IR after 7 years of 
suppressive cART.
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Methods
Study design
In a randomised double-blind crossover placebo-controlled trial, individuals with SO-IR 
(patients with CD4 increase <295 cells after 7 years of suppressive cART) were randomised 
to atorvastatin, 80 mg daily or placebo for 12 weeks (phase 1). Upon completion of phase 1, 
participants had a 4-week washout period, subsequently switching treatment assignments to 
complete an additional 12 weeks (phase 2) in the opposite assignment (Figure 1).
Study setting
This clinical trial was nested within the Infectious Diseases Institute (IDI) research cohort of 
adults that have received cART for at least 7 years. Between April 2004 and April 2005, 559 
consecutive cART-naïve HIV-infected patients were initiated on cART and enrolled into the 
IDI prospective observational research cohort as previously described (Kamya & Mayanja-
Kizza 2007). Patients were initiated on first-line cART at CD4 counts ≤200 cells/μl 
according to Ugandan guidelines for cART initiation at the time. Drugs were provided 
through the Global Fund [a generic combined formulation of stavudine (d4T), lamivudine 
(3TC) and nevirapine (NVP)] and the US President’s Emergency Plan for AIDS Relief [a 
combined formulation of zidovudine (ZDV) and 3TC plus efavirenz (EFZ) or nevirapine 
(NVP)]. Patients with toxicity to ZDV were changed to tenofovir (TDF). All patients 
received cotrimoxazole (or dapsone) prophylaxis according to the national policy to provide 
cotrimoxazole to all PLHIV. Adherence to cART was encouraged by at least three 
individual and group counselling sessions. Patients were reviewed monthly by the study 
physicians, who evaluated adherence to medication, toxicities and acute infections. HIV 
RNA viral loads, complete blood counts and CD4 lymphocyte counts were measured at 6-
monthly intervals.
Study population
After 7 years of cART, 121 patients were still receiving first-line cART and had sustained 
viral suppression (HIV RNA levels < 400 copies/ml) from 6 months post-cART initiation. 
The CD4 increase from baseline (at cART initiation) to current CD4 (at 7 years) was 
calculated and grouped into quartiles. Patients in the lowest quartile of CD4 increase with 
mean CD4 increase of 190 (minimum–maximum, −13 to 295) cells were grouped as ‘sub-
optimal immune responders (SO-IR)’, n = 31, while patients in the highest quartile of CD4 
increase were grouped as ‘optimal responders’, n = 30 with a mean CD4 increase of 823 
(minimum–maximum, 581–1572) cells (Figure 1). We included 30 healthy HIV-negative, 
age- and gender-matched individuals consecutively selected from the HIV-negative patient 
register at Mulago routine HIV testing programme that is adjacent to the infectious diseases 
clinic, as a comparative group of immune activation in our healthy HIV-negative population. 
Ethical approval was provided by the Uganda National Council for Science and Technology, 
the national research ethical regulatory body and the National Drug Authority. The study 
was conducted according to the Declaration of Helsinki. All participants provided written 
informed consent to participate in the study. The clinical trial was registered by the Pan 
African Clinical Trial Registry at www.pactr.org (PACTR201301000445375). This trial was 
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monitored by independent medical monitors under the IDI clinical trials unit, and a data 
safety monitoring board to ensure patient safety and protocol adherence.
We included HIV-infected adults receiving cART for at least 7 years, with a current CD4 < 
295 cells/μl despite sustained viral suppression. We excluded pregnant women, individuals 
with a history of myositis, abnormal liver function tests, history of ingestion of lipid-
lowering agents or use of therapeutic agents known to have substantial drug–drug 
interactions with statins such as protease inhibitors (PI)-containing cART. PIs increase 
atorvastatin area under the curve by 5.9 fold and may increase statin-induced toxicity 
(Alluvia Product characteristics). We also excluded individuals with a current opportunistic 
infection or febrile illness to avoid interference with our primary outcome of immune 
activation.
Randomisation and blinding
Combination antiretroviral therapy-treated SO-IR were randomised to atorvastatin [80 mg (2 
tablets) daily for 12 weeks] and placebo (two tablets daily), as adjunct therapy. Both placebo 
and atorvastatin were identical in appearance, supplied by Pfizer under investigator initiated 
research (Pfizer Reference # WI171060). Assignment of the drug and placebo, using 
computer-generated sequences, was completed by a pharmacist who was not involved with 
the clinical conduct of the study. Study clinicians were blinded to drug assignments with 
patient arm denoted as drug A and drug B. Patients’ clinical care results were reviewed in 
real time by an independent IDI research cohort doctor (not participating in the atorvastatin 
trial) as part of routine follow-up of patients in HIV treatment cohort.
Patient follow-up
Patients had scheduled follow-up visits weekly in the first 4 weeks, and thereafter bi-weekly 
until completion of a study phase. Unscheduled patient visits were encouraged for any 
illnesses. Each scheduled clinical visit included clinical assessment for any expected/
unexpected illnesses and adherence monitoring by self-report and pill counts for both 
antiretroviral drugs and study drug. Ongoing counselling and adherence support was 
provided by the study counsellor.
Laboratory procedures
Patients had blood draws at initiation of the study drug, at weeks 12, 16 and 28. At each 
blood draw, complete blood counts, liver function tests and fasting serum lipid profile were 
measured at MBN Clinical laboratory, Kampala, Uganda within 2 h of sample collection.
Peripheral blood mononuclear cells separation
Forty millilitres of whole blood, collected in acid citrate dextrose solution A vacutainers 
(BD VacutainerTM), were processed for Peripheral blood mononuclear cell (PBMC) 
separation within 2 h of collection. PBMCs were separated by Ficoll–Hypaque density 
configuration, washed and resuspended in phosphate buffer saline (PBS) containing heat-
inactivated foetal calf serum (FCS). PBMCs were frozen and stored in FCS with 10% 
dimethyl sulfoxide (DMSO), in liquid nitrogen until assay time.
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Immunophenotyping
Cryopreserved PBMC was thawed and batch analysed to ensure consistency, using an LSRII 
flow cytometer (BD Biosciences) at Uganda Virus Research Institute/Medical Research 
Council basic science laboratory. Cell surface staining was used to phenotype the markers 
for T-cell activation and exhaustion using antibodies for CD3- Amcyan, CD4- Pacific blue, 
HLADR-PerCP cy5.5, CD38-APC, PD-1-PE and Live/dead marker-FITC (BD Biosciences). 
Overall, at least 500 000 events in the CD3-positive gate were collected. The gating was 
standardised and set using fluorescence minus one controls for HLADR, CD38 and PD1 as 
shown in Figure 2. Percentages of activated T cells were determined by the proportion of 
CD3 + CD4 + (CD8) CD38 + HLADR+ T cells, and immune exhaustion was determined by 
the percentage of T cells expressing programmed cell death marker-1 (CD3 + CD4 + (CD8) 
PD-1) as shown in Figure 2.
Primary outcome
The primary outcome of the trial was the change in CD4 T-cell activation levels during the 
12-week intervention, in view of poor CD4 T-cell function observed among the suboptimal 
immune responders with persistently high immune activation levels despite suppressive 
antiretroviral therapy (Nakanjako et al. 2011, 2013). Change in CD8 T-cell activation and 
change in immune exhaustion markers were secondary outcomes.
Statistical analysis
With a sample size of 30 (15 in each arm), this study had 80% power to detect a 0.25 
difference in reduction of immune activation in the atorvastatin and placebo arm, with a 
statistical significance at P-value < 0.05. To assess the effects of treatment, we calculated 
the difference in changes, for immune activation and exhaustion parameters, while a 
participant was receiving atorvastatin or placebo. Pre- and post-treatment T-cell activation, 
percentage of activated T cells (CD3 + CD4 + (CD8)CD38 + HLADR+ cells) and 
exhaustion (CD3 + CD4 + (CD8)PD1 + ) were compared among SO-IR on atorvastatin 
(ATV) and placebo using the Mann–Whitney test for non-parametric tests. Additional 
analysis was carried out to determine carry-over and period effects using ANOVA test and 
the pk cross-STATA command. Given that there were no significant carry-over and period 
effects, results were presented for all the 30 participants for 12 weeks on atorvastatin vs. 
placebo. In addition, post-treatment immune activation and exhaustion were compared with 
the parameters among healthy donors from the same environment. Flow cytometry data 
were analysed using FlowJO software version and comparisons analysed using Prism Graph 
Pad 5.0 software and STATA version 11.0.
Results
Demographic and clinical characteristics, including cART drug regimen, hypertension and 
biometric profile, haematology and liver function, were comparable among individuals 
randomised to atorvastatin and placebo (Table 1).
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T-cell activation markers
Twelve weeks of atorvastatin adjunct therapy to cART showed a 28% higher reduction in 
percentage of activated CD4 T cells than placebo and cART; median percentage of activated 
CD4 T cells [Interquartile range (IQR), from 4.2 (3.7–6.2) to 1.7 (1.6–3.1) in the atorvastatin 
arm, P = 0.001 and from 2.9 (2.9–5.0) to 2.0 (2.3–4.9) in the placebo arm, P = 0.190]. A 12-
week atorvastatin and cART also led to a 35% higher reduction in percentage of activated 
CD8 T cells than cART and placebo, from 2.6 (2.5–5.0) to 1.3 (1.1–1.9) in the atorvastatin 
arm, P = 0.0009 and from 2.1 (2.0–4.7) to 1.9 (1.4–3.3) in the placebo arm, P = 0.203 
(Figure 3). There was no carry-over (P = 0.539) or period effect (P = 0.865).
T-cell exhaustion
Twelve weeks of atorvastatin adjunct therapy to cART showed a 14% higher reduction in 
the percentage of exhausted CD4 T cells (CD3 + CD4 + PD1 + ) than placebo; from 26.0 
(24.5–32.5) to 19.0 (16.9–22.6) in the atorvastatin arm, P = 0.004 and from 29.2 (25.4–32.5) 
to 25.3 (22.2–30.2) in the placebo arm, P = 0.271. In addition, 12 weeks of cART and 
atorvastatin showed an 11% higher reduction in percentage of exhausted CD8 T cells from 
16.7 (14.9–20.5) to 12.1 (10.5–14.8) in the atorvastatin arm, P = 0.004 and from 16.9 (14.9–
20.0) to 14.2 (12.3–17.9) in the placebo arm, P = 0.128 (Figure 3). Post-therapy T-cell 
activation and exhaustion (for both atorvastatin and placebo) were significantly higher than 
levels among healthy HIV-negative individuals from the same community (data not shown). 
The smallest reductions in immune activation were noted among patients receiving an 
efavirenz-containing cART regimen while the four highest reductions in immune activation 
were noted among patients receiving a nevirapine-containing cART regimen.
Safety and tolerability
Atorvastatin (80 mg daily) was well tolerated as adjunct to nevirapine and efavirenz-
containing first-line cART. Liver function tests were comparable among HIV-infected adults 
receiving cART plus atorvastatin and individuals receiving cART and placebo (Table 2).
Lipid profile
Low-density lipoprotein (LDL) and triglycerides reduced significantly among individuals 
receiving atorvastatin after 12 weeks of therapy in phase 1 (P-value 0.0006) and phase 2 (P-
value 0.014) (Table 2).
Adverse events
Expected adverse events were comparable among individuals on atorvastatin (12) and 
placebo (9), with myalgias as the commonest in six individuals (three in atorvastatin and 
three in placebo arms), followed by chest pain in four individuals (three in atorvastatin and 
one in placebo arms), headache in four individuals (one in atorvastatin and three in placebo 
arms) and arthralgia in three individuals (two in atorvastatin and one in placebo arm). Other 
expected adverse events included backache (1), neck pain (1), left forearm pain (1); only 
reported in the atorvastatin arm). All adverse events resolved spontaneously without 
unblinding of study participants.
Nakanjako et al. Page 6
Trop Med Int Health. Author manuscript; available in PMC 2015 August 08.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Discussion
We found that short-term adjunct therapy with high-dose atorvastatin decreased CD4 and 
CD8 activation and exhaustion among cART-treated adults with 7 years of suppressive 
cART in an African cohort. To our knowledge, this is the first study to report use of 
atorvastatin as adjunct to cART in SSA, where individuals reportedly have high background 
immune activation due to several endemic infections such as malaria, intestinal helminths 
and tuberculosis (Borkow et al. 2001; Coban et al. 2005).
Our results are consistent with a previous clinical trial in the USA where high-dose 
atorvastatin (80 mg daily) was reported to decrease CD4 and CD8 T-cell activation among 
cART-naive HIV-infected adults, as an incidental finding, although atorvastatin did not 
demonstrate antiretroviral properties (Ganesan et al. 2011). Similarly, previous studies in 
USA and Europe reported anti-inflammatory effects of statins during HIV infection (Ono & 
Freed 2001; del Real et al. 2004; Giguere & Tremblay 2004) and in management of 
atherosclerosis (Jain & Ridker 2005). Statins have been widely prescribed for their 
cholesterol-lowering properties and efficacy in cardiovascular disease; however, compelling 
evidence now exists that statins also have extensive immunomodulatory properties that 
operate independently (Greenwood et al. 2006). Statins also act as direct inhibitors of 
induction of MHC-II expression by IFN-gamma and thus as repressors of MHC-II-mediated 
T-cell activation, through inhibition of the inducible promoter IV of the transactivator 
CIITA in several cell types, including primary human endothelial cells and monocyte–
macrophages (Kwak et al. 2000).
In view of previous reports that T-cell immune activation and exhaustion were associated 
with poor immune recovery and mortality during antiretroviral therapy (Nakanjako et al. 
2008, 2011; Hunt et al. 2011), our current report of anti-immune activation effects of 
atorvastatin presents an opportunity for utilisation of atorvastatin and probably other statins 
to optimise immune recovery among cART-treated HIV-infected individuals in Africa. In 
addition, use of atorvastatin to reduce immune activation could be explored in the 
management of the immune reconstitution inflammatory syndrome (IRIS), which is 
reportedly associated with high levels of immune activation (Bonham et al. 2008; Goovaerts 
et al. 2013). Furthermore, with the evidence that persistent immune activation during 
chronic HIV infection was associated with increased risk of non-AIDS illnesses (NADIS) 
such as atherosclerosis and kidney diseases (Gupta et al. 2009; Crowe et al. 2010; Kaplan et 
al. 2011), there are potential benefits of atorvastatin therapy in the reduction of NADIS 
among adults ageing with HIV. It is important to note that atorvastatin demonstrated the 
conventional lipid-lowering effects in our study participants, consistent with previous 
reports of reduced cardiovascular risk associated with use of atorvastatin (Ray & Cannon 
2005; Acharjee & Welty 2008). Therefore, atorvastatin adjunct therapy could benefit cART-
treated individuals through its reduction of persistent immune activation associated with 
chronic HIV infection (Hunt et al. 2011; Nakanjako et al. 2011) and through its known 
lipid-lowering effects among cART-treated adults at risk of atherosclerosis (Ssinabulya et 
al. 2014).
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However, we observed that effects of atorvastatin were not carried over through the washout 
period and the effects were independent of the sequence of interventions. Our study implies 
that HIV-infected cART-treated individuals might benefit from long term rather than short-
term use of atorvastatin. This finding is similar to previous reports of improved clinical 
outcomes among elderly individuals receiving long-term atorvastatin (Ray & Cannon 2005; 
Acharjee & Welty 2008). One unexplained finding is the observed rise in immune activation 
during the washout period in both study arms, although relatively higher among the 
individuals that started with atorvastatin. We postulate that it could be due to environmental 
variation of other possible causes of immune activation that were not evaluated in our study. 
However, we believe that such variation did not interfere with interpretation of our data 
given the randomised crossover study design.
Safety and tolerability of atorvastatin during antiretroviral therapy
We used the highest FDA-approved dose of atorvastatin for maximal lipid-lowering effects 
previously used among cART-naive HIV-infected adults (Ganesan et al. 2011). High-dose 
atorvastatin was well tolerated as adjunct therapy to nevirapine and efavirenz-based cART 
regimen. Our findings are consistent with recent clinical trials that demonstrated minimal 
adverse events with high statin doses, such as 0.6% serious hepatic and 1.3% musculo-
skeletal adverse effects (Archbold & Timmis 1998; LaRosa et al. 2005). In addition, the 
Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL), 
Treating to New Targets (TNT), Pravastatin or Atorvastatin Evaluation and Infection 
Therapy – Thrombolysis in Myocardial Infarction 22 (PROVE ITTIMI 22) and Stroke 
Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trials, have shown 
that high-dose statins, especially atorvastatin 80 mg, can reduce vascular risks more than 
low or moderate-dose statin therapy (Archbold & Timmis 1998; LaRosa et al. 2005). 
Pharmacokinetics trials previously showed that efavirenz reduced atorvastatin exposure by 
43% and the total active atorvastatin by 34% (Gerber et al. 2005). Although we did not 
conduct pharmacokinetic studies, the four least reductions in immune activation were 
recorded among patients receiving an efavirenz-containing regimen. It is therefore likely 
that the reduced inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) 
reductase activity during co-administration of efavirenz may have resulted in diminished 
therapeutic effects of atorvastatin. In the management of acute coronary syndromes, 
atorvastatin 80 mg was well tolerated and resulted in better clinical outcomes than standard 
care with pravastatin 40 mg (Ray et al. 2005). Given the known benefits of high-dose 
atorvastatin therapy, our study implies additional benefit of adjunct atorvastatin therapy 
among HIV-infected adults receiving antiretroviral therapy. We therefore recommend 
further studies to determine the optimal dosing of atorvastatin, as adjunct therapy to non-
nucleoside reverse transcriptase inhibitor (NNRTI)-containing cART.
A major strength of our study was the randomised double-blinded crossover design that 
controlled for confounders of individuals’ immune activation levels (Sibbald & Roberts 
1998; Valentinuzzi 2004). Twelve weeks’ administration of atorvastatin did not show 
significant effect on absolute CD4 count (data not shown), probably because of the short 
duration of therapy. Therefore, further research is required to determine long-term 
immunological benefits of high-dose atorvastatin adjunct therapy. We did not evaluate other 
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causes of immune activation in this environment that could have accounted for the 
increasing levels of immune activation during the wash-out period. However, post-treatment 
immune activation levels remained significantly higher than immune activation levels 
among age- and gender-matched healthy HIV-negative individuals selected from the same 
setting. Nevertheless, our proof of concept that atorvastatin adjunct therapy provides 
additional reduction of immune activation may inform the development of larger and longer 
studies to evaluate the effect of atorvastatin adjunct therapy on HIV treatment outcomes.
Conclusion
Atorvastatin reduced T-cell immune activation and exhaustion among cART-treated adults 
with suboptimal immune recovery in an urban Ugandan cohort. Atorvastatin adjunct therapy 
should be explored as a strategy to improve HIV treatment outcomes among cART-treated 
adults with persistently high levels of immune activation.
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Figure 1. 
Profile of CD4 increase among 121 adults with sustained viral suppression for 7 years in the 
Infectious Diseases Institute research cohort.
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Figure 2. 
Gating strategy for T-cell activation and exhaustion. (a) shows singlets/duplets, (b) shows 
FSC with lymphocyte gate, (c) shows the live gate, (d) shows CD3 + CD4 + T cells, (e) 
shows CD38-APC vs. fluorescence minus one (FMO) HLADR-PerCP cy5.5, (f) shows 
FMO CD38-APC vs. HLADR- PerCP cy5.5, (g) shows CD4 T-cell activation (CD3 + CD4 
+ CD38 + HLADR+) and (h) shows CD8 T-cell activation (CD3 + CD8 + CD38 + HLADR
+), (i) shows programmed death (PD-1) FMO, (j) shows CD4 T-cell exhaustion (CD3 + 
CD4 + PD1 + ) and (k) shows CD8 T-cell exhaustion (CD3 + CD8 PD1 + ).
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Figure 3. 
T-cell activation among cART-treated suboptimal immune responders before and after use 
of atorvastatin 80 mg daily vs. placebo. All 30 participants are presented for the 12 weeks on 
study drug (atorvastatin) vs. placebo. (a) Shows percentages of activated CD4 T cells, (b) 
shows percentages of activated CD8 T cells, (c) shows percentages of exhausted CD4 T 
cells and (d) shows percentages of exhausted CD8 T cells. The whiskers represent the 
interquartile ranges. The non-parametric Mann–Whitney test was used to compare immune 
activation in the study groups, with statistical significance at P-value ≤ 0.05.
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Table 1
Baseline characteristics of HAART-treated HIV-infected adults with suboptimal immune response within the 
IDI research cohort
Variables
Active drug
first (N = 15)
Placebo first
(N = 15)
Demographic data
 Female n (%) 7 (46.7) 10 (66.7)
 Median age (IQR) 41 (40–50) 47 (43–51)
 Marital status n (%)
  Married/cohabiting 10 (66.7) 6 (40.0)
  Divorced 3 (20.0) 4 (26.7)
  Widowed 2 (13.3) 5 (33.3)
 Occupation n (%)
  Unemployed 4 (26.7) 2 (13.3)
  Employed 11 (73.3) 13 (86.7)
 Education n (%)
  Primary 6 (40.0) 6 (40.0)
  Secondary and above 9 (60.0) 9 (60.0)
 CD4 at HAART initiation, median (IQR) 78 (43–162) 92 (50–130)
First-line HAART regimen, n (%)
 ZDV+3TC+NVP 5 (33.3) 7 (46.7)
 ZDV+3TC+EFZ 5 (33.3) 3 (20.0)
 TDF+FTC+EFZ 1 (6.7) 0 (0.0)
 TDF+FTC+NVP 1 (6.7) 0 (0.0)
 Others 2 (13.3) 3 (20.0)
Concurrent medication*
 Antihypertensive n (%) 0 (0.0) 3 (20)
 Cotrimoxazole prophylaxis 15 (100) 14 (87)
 Fluconazole 0 (0) 1 (7)
Physical examination
 Axillary temperature, median (IQR) 36.0 (35.7–36.4) 36.1 (35.8–36.4)
 BMI, median (IQR) 20.8 (19.5–21.6) 24.0 (21.1–26.4)
 Waist circumference, median (IQR) 79.0 (72.0–80.0) 88.0 (77.0–96.0)
 Hip circumference, median (IQR) 88.0 (86.0–95.0) 97.0 (93.0–104.0)
 Median waist to hip ratio(IQR) 0.9 (0.8–0.9) 0.9 (0.9–1.0)
 Median pulse rate (IQR) 80.0 (70.0–92.0) 84.0 (77.0–94.0)
 Systolic blood pressure, median (IQR) 110 (100–149) 140 (112– 163)
 Diastolic blood pressure, median (IQR) 74 (65–82) 89 (70–100)
HB (g/dl), median (IQR) 14 (12.9–15.2) 13.1 (12.2–14.2)
WBC (103 cells/Ul), median (IQR) 3.6 (2.8–3.8) 3.45 (3.0–4.1)
ESR (mm/h), median (IQR) 11 (3–15) 11 (3–15)
*No participants had any history of medication with non-steroidal anti-inflammatory drugs (NSAIDS), steroids, use of statins, family history of 
stroke and sudden death, febrile illness or confirmed malaria within 2 weeks preceding the study.
WBC, White blood cell count, normal adult range, 4.0–11.0 × 103 cells/Ul; HB, haemoglobin, normal range, 12–18 g/dl; ESR, erythrocyte 
sedimentation rate, normal range (male, female, elderly, up to 10, 15, 20 mm/h).
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Table 2
Liver function tests and fasting lipid profile of participants by study arm
Laboratory parameter,
Median (IQR) Week Placebo Active drug P-value†
AST (U/l) 0 35.8 (25.3, 55.9) 35.8 (24.5, 43.8) 0.458
12 32.8 (25.9, 44.3) 32.6 (25.6, 44.6) 0.852
16 34.6 (26.5, 45.9) 33.3 (26.9, 41.4) 0.561
28 32.3 (23.7, 49.0) 32.1 (23.6, 45.4) 0.458
ALT(U/l) 0 18.1 (11.1, 32.9) 15.6 (11.1, 32.9) 0.694
12 15.1 (9.1, 20.6) 13.3 (6.2, 17.6) 0.272
16 16.0 (12.6, 26.3) 15.9 (10.9, 23.4) 0.319
28 14.6 (7.2, 19.9) 11.9 (7.2, 21.1) 0.948
HDL (mmol/l) 0 1.7 (1.5, 2.0) 1.7 (1.6, 1.8) 0.726
12 1.7 (1.5, 2.0) 1.5 (1.2, 1.9) 0.113
16 1.9 (1.6, 2.5) 1.6 (1.6, 2.0) 0.492
28 1.5 (1.3, 1.6) 1.5 (1.3, 1.8) 0.380
LDL (mmol/l) 0 4.9 (2.4, 6.7) 3.1 (2.2, 4.9) 0.222
12 4.2 (2.1, 6.4) 1.0 (0.9, 2.5) 0.0006***
16 3.8 (2.5, 6.4) 2.3 (1.9, 4.8) 0.097
28 1.9 (1.3, 3.1) 2.1 (1.7, 5.1) 0.239
Triglycerides (mmol/l) 0 2.0 (1.4, 3.2) 1.6 (1.1, 2.4) 0.089
12 1.7 (0.9, 2.2) 1.0 (0.7, 2.1) 0.014*
16 2.6 (1.3, 3.5) 1.7 (1.2, 2.8) 0.178
28 1.5 (1.2, 2.1) 1.5 (1.2, 2.3) 0.663
†
Mann–Whitney test.
*
P value < 0.05,
***
P value < 0.001
AST, Aspartate aminotransferase, normal range 0–40 μl; ALS, alanine aminotransferase, normal range 0–40 μl; HDL, high-density lipoprotein, 
normal range 1–1.8 mmol/l; LDL, low-density lipoprotein, normal range up to 4.4 mmol/l.
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